Skip to main content

Table 3 Incidences of complications or adverse events during Impella 5.0 support

From: Management and outcome of patients supported with Impella 5.0 for refractory cardiogenic shock

Type of complication

Values

Major device malfunction, n (%)

4 (10)

Minor device malfunction, n (%)

3 (8)

Device displacement (intra-aortic or intraventricular moving), n (%)

8 (20)

 Including successful bedside repositioning, n

6

Bleeding requiring transfusion during surgical implantation, n (%)

7 (18)

Bleeding requiring surgery after implantation, n (%)

0 (0)

RBC transfusion on MCS, units [IQR]

4 [1.5–8]

RBC transfusion by day on MCS, units [IQR]

0.4 [0.1–1.2]

Upper or lower limb ischemia on implantation site, n (%)

1 (3)

Thromboembolic events, n (%)

1 (3)

Major hemolysis, n (%)

1 (3 %)

Suspected or minor hemolysis, n (%)

3 (8 %)

Ventricular arrhythmia, n (%)

3 (8)

Device-related infection, n (%)

7 (18)

 Surgical site infection, n (%)

4 (10)

 Infected thrombus on the head of the pump, n (%)

3 (8)

 Bloodstream infection during MCS, n (%)

5 (13)

  1. Major hemolysis: anemia without bleeding associated with an increase of free bilirubin and lactate dehydrogenase (LDH). Suspected or minor hemolysis: low increase of free bilirubin and LDH without unexplained anemia
  2. RBC red blood cells, MCS mechanical circulatory support, IQR interquartile range